INTRAVITREAL CONBERCEPT (KH902) FOR SURGICAL TREATMENT OF SEVERE PROLIFERATIVE DIABETIC RETINOPATHY. Issue 5 (May 2016)

• Record Type: Journal Article
• Authors: Su, Long; Ren, Xinjun; Wei, Huiyu; Zhao, Li; Zhang, Xiaomin; Liu, Juping; Su, Chang; Tan, Liangzhang; Li, Xiaorong
• Is Part Of: Retina. Volume 36:Issue 5(2016:May)
• Publication Date: 2016-05
• Subjects: conbercept -- proliferative diabetic retinopathy -- tractional retinal detachment -- vitrectomy; Retina -- Diseases -- Periodicals; Retinal Diseases; Vitreous Body; 617.735
• DOI: 10.1097/IAE.0000000000000900
• Languages: English
• ISSNs: 0275-004X

Abstract

Abstract : Purpose: To evaluate the role, safety, and effectiveness of intravitreal conbercept (KH902) injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy. Methods: A randomized controlled trial was performed on 36 eyes of 36 patients affected by vitreous hemorrhage and tractional retinal detachment, which occurred as a consequence of active proliferative diabetic retinopathy. The patients were randomly assigned to two groups. The patients in one of the groups received an intravitreal injection of conbercept in the inferior temporal sector 4 mm from the sclerocorneal limbus with a sterile technique 1 week before vitrectomy. Results: In the group without conbercept, intraoperative bleeding occurred in 14 patients (77.8%), and in five of these cases, bleeding was significant. The use of endodiathermy was necessary in 8 patients (44.4%). In 3 patients (16.6%), iatrogenic retinal breaks occurred, and in 1 patient (5.5%), a relaxing retinotomy was performed. Endotamponade with silicone oil was performed in 12 patients (66.6%). In the group treated with conbercept, intraoperative bleeding occurred in 2 cases (11.1%). The use of endodiathermy was necessary in 1 patient (5.5%). No patients experienced iatrogenic breaks or relaxing retinotomy during the surgery. Endotamponade with silicone oil was performed in 2 patients (11.1%). Conclusion: Preoperative intravitreal injection of conbercept could reduce the chances of intraoperative bleeding, which are beneficial in the management of proliferative diabetic retinopathy. Abstract : A preoperative intravitreal injection of conbercept may represent another new strategy for the surgical treatment of severe proliferative diabetic retinopathy by reducing retinal and iris neovascularization. This would make surgery much easier and safer, thus improving the anatomical and functional prognosis.